Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 2851-2857

  Tell, Roger ^a,h   Sederholm, Christer ^b   Klintenberg, Claes ^b   Franksson, Lars ^a   Brandén, Eva ^a,c   Hillerdal, Gunnar ^a   Lönn, Ulf ^c   Lindén, Carl Johan ^d   Ewers, Sven Börje ^d   Lamberg, Kristina ^e   Mrazek, Eva ^e   Lödén, Britta ^f   Sjögren, Anders ^f   Linné, Thomas ^g   Friesland, Signe ^a   Sirzén, Florin ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c GÄVLE HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e CENTRAL HOSPITAL   (Sweden)

^f CENTRAL HOSPITAL   (Sweden)

^g BRISTOL MYERS SQUIBB   (United States)

^h Eli Lilly Sweden AB   (Sweden)

Author keywords

Carboplatin; Chemoradiotherapy; Induction chemotherapy; Non small cell lung cancer; Paclitaxel; Phase II study

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; ESOPHAGITIS; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SURVIVAL RATE;

EID: 55749084737     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Cancer Incidence in Sweden 2006. The National Board of Health and Welfare, Centre for Epidemiology. Stockholm; Published December 19, 2007 at Internet.
2. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Adjei AA, Jett J and Deschamps C: Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 128: 452-462, 2005.
3. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997.
4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311: 899-909, 1995.
5. Auperin A RE, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Stewart L and Le Pechoux C on behalf on the NSCLC Collaborative Group: Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC). A meta-analysis using individual patient data from randomised clinical trials. J Thorac Oncol 2: S310, 2007.
6. Pritchard RS and Anthony SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer. A meta-analysis. Ann Intern Med 125: 723-729, 1996.
7. Sause W, Kolesar P, Taylor SI, Johnson D, Livingston R, Komaki R, Emami B, Curran W Jr, Byhardt R, Dar AR and Turrisi A, 3rd: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117: 358-364, 2000.
8. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY and Laplanche A: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83: 417-423, 1991.
9. Dillman R, Herndon, J, Seagren, SL, Eaton, WL Jr and Green MR: Improved survival in stage III non-small cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88: 1210-1215, 1996.
10. Jeremic B, Shibamoto Y, Acimovic L and Milisavljevic S: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized study. J Clin Oncol 14: 1065-1070, 1996.
11. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N and Ariyoshi Y: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17: 2692-2699, 1999.
12. Chang A, Kim K, Click J, Anderson T, Karp D and Johnson D: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 85: 388-394, 1993.
13. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, Davilla E LJ, Dhingra H, Raber MN, Krakoff IH and Hong WK: Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85: 384-388, 1993.
14. Gatzemeier U, Heckmayr M, Neuhauss R, Schluter I, Pawel JV, Wagner H and Dreps A: Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer 12: S101-106, 1995.
15. Hainsworth JD, Urba WJ, Hon JK, Thompson KA, Stagg MP, Hopkins LG, Thomas M and Greco FA: One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial. Eur J Cancer 34: 654-658, 1998.
16. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M and De Vore RF, 3rd: Paclitaxel plus carboplatin in advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 14: 2054-2060, 1996.
17. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S and Ozols RF: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 13: 1860-1870, 1995.
18. Natale RB: Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Semin Oncol 23: 51-54, 1996.
19. Evans WK, Earle CC, Stewart DJ, Dahrouge S, Tomiak E, Goss G, Logan D, Goel R, Gertler SZ and Dulude H: Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer. Lung Cancer 18: 83-94, 1997.
20. Choy H, Safran H, Akerley W, Graziano SL, Bogart JA and Cole BF: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 4: 1931-1936, 1998.
21. Choy H, Devore RF, 3rd, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y and Johnson DH: A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 47: 931-937, 2000.
22. Marangolo M, Emiliani E, Rosti G, Giannini M, Vertogen B and Zumaglini F: Phase I/II study of paclitaxel and radiotherapy in non-small cell lung cancer. Semin Oncol 23: 124-127, 1996.
23. Rowinsky EK, Cazenave LA and Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259, 1990.
24. Haldar S, Chintapalli J and Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
25. Milas L, Hunter NR, Mason KA, Kurdoglu B and Peters LJ: Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 54: 3506-3510, 1994.
26. Begg A, van der Kolk PJ, Emondt J and Bartelink H: Radiosensitization in vitro by cis-diammine (1,1-cyclobutane-dicarboxylato) platinum(II) (carboplatin, JM8) and ethylene-diammine-malonatoplatinum(II) (JM40). Radiother Oncol 9: 157-165, 1987.
27. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J and Norton L: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353-3361, 1998.
28. Schwachofer JH, Crooijmans RP, Hoogenhout J, Kal HB and Theeuwes AG: Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: influence of treatment sequence. Int J Radiat Oncol Biol Phys 20: 1235-1241, 1991.
29. Skov K and MacPhail S: Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and tetraplatin. Int J Radiat Oncol Biol Phys 20: 221-225, 1991.
30. National Cancer Institute. Common Toxicity Criteria, Version 2.0. 1998.
31. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151, 1982.
32. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 327: 1434-1441, 1992.
33. Trovo MG, Minatel E, Veronesi A, Roncadin M, De Paoli A, Franchin G, Magri DM, Tirelli U, Carbone A and Grigoletto E: Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study. Cancer 65: 400-404, 1990.
34. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF, 3rd and Green MR: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323: 940-945, 1990.
35. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87: 198-205, 1995.
36. Komaki R: Combined chemotherapy and radiation therapy in surgically unresectable regionally advanced non-small cell lung cancer. Semin Radiat Oncol 6: 86-91, 1996.
37. Roach M, 3rd, Gandara DR, Yuo HS, Swift PS, Kroll S, Shrieve DC, Wara WM, Margolis L and Phillips TL: Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 13: 2606-2612, 1995.
38. Belani CP: Multimodality management of regionally advanced non-small-cell lung cancer. Semin Oncol 20: 302-314, 1993.
39. Choy H, Rodriguez FF, Koester S, Hilsenbeck S and Von Hoff DD: Investigation of taxol as a potential radiation sensitizer. Cancer 71: 3774-3778, 1993.
40. Rolland E LCT, Auperin A Burdett S, Pignon JP on behalf of the NSCLC Collaborative Group: Sequential radio-chemotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced non-small cell lung cancer: Two meta-analysis using individual patient data from randomised clinical trials. J Thorac Oncol 2: S309, 2007.
41. Marino P, Preatoni A and Cantoni A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 76: 593-601, 1995.
42. Belani CP, Choy H, Bonomi P, Scott C, Travis P and Haluschak J, and Curran WJ Jr: Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23: 5883-5891, 2005.
43. Vokes EE, Herndon JE, 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W and Green MR: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25: 1698-1704, 2007.
44. Vokes EE, Herndon JE, 2nd, Crawford J, Leopold KA, Perry MC, Miller AA and Green MR: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20: 4191-4198, 2002.
45. Hanna NH NM, Ansari R, Govindan R, Bruetman D, Fisher W, Chowhan N, Nattam S, Yiannoutsos C and Einhorn L: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. J Clin Oncol 25: 7512, 2007.
46. Sirzen F, Kjellen E, Sörenson S and Cavallin-Ståhl E: A systematic overview of radiation therapy effects in non-small cell lung cancer. Acta Oncol 42: 493-515, 2003.
47. Blomgren H, Lax I, Näslund I and Svanström R: Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 34: 861-870, 1995.
48. Blackstock AW and Govindan R: Definitive chemoradiation for the treatment of locally advanced non-small cell lung cancer. J Clin Oncol 25: 4146-4152, 2007.
49. Okawara G, Mackay JA, Evans WK and Ung YC: Management of unresected stage III non-small cell lung cancer: a systematic review. J Thorac Oncol 1: 377-393, 2006.
50. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT and Somerfield MR: American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353, 2004.
51. Rowell NP and O'Rourke NP: Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev: CD002140, 2004.